Last 12 months
Inside the activity.
2 purchase rows · 26 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 15 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 2 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2022 Filed Aug 16, 2022 21:36 UTC |
EMPFIELD JAMES R.EVP, Drug Discovery
|
Exercise / conversionCommon Shares | 20,000 | $3.10 | $62,000.00 |
DisclosureSEC source: 0001209191-22-046017 · doc4.xml · nonDerivative · entry 1 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2022 Filed Jun 29, 2022 21:26 UTC |
GANNON STEVENDirector
|
GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $30.11 | $0.00 |
DisclosureSEC source: 0001209191-22-039827 · doc4.xml · derivative · entry 1 GANNON STEVEN · CIK 0001643085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Shares · 18,000 shares Expires 2032-06-27 F1 · derivative.exercise_date: 100% of the common shares subject to the option will vest on the earlier of (i) the first anniversary of grant date and (ii) the day immediately preceding the day of the Issuer's next annual general meeting of shareholders. Read SEC document |
| June 28, 2022 Filed Jun 29, 2022 17:48 UTC |
PIMSTONE SIMON N.Director
|
GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $30.11 | $0.00 |
DisclosureSEC source: 0001209191-22-039837 · doc4.xml · derivative · entry 1 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Shares · 18,000 shares Expires 2032-06-27 F1 · derivative.exercise_date: 100% of the common shares subject to the option will vest on the earlier of (i) the first anniversary of grant date and (ii) the day immediately preceding the day of the Issuer's next annual general meeting of shareholders. Read SEC document |
| June 28, 2022 Filed Jun 29, 2022 21:34 UTC |
Machado PatrickDirector
|
GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $30.11 | $0.00 |
DisclosureSEC source: 0001209191-22-039831 · doc4.xml · derivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Shares · 18,000 shares Expires 2032-06-27 F1 · derivative.exercise_date: 100% of the common shares subject to the option will vest on the earlier of (i) the first anniversary of grant date and (ii) the day immediately preceding the day of the Issuer's next annual general meeting of shareholders. Read SEC document |
| June 28, 2022 Filed Jun 29, 2022 21:40 UTC |
PATOU GARYDirector
|
GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $30.11 | $0.00 |
DisclosureSEC source: 0001209191-22-039833 · doc4.xml · derivative · entry 1 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Shares · 18,000 shares Expires 2032-06-27 F1 · derivative.exercise_date: 100% of the common shares subject to the option will vest on the earlier of (i) the first anniversary of grant date and (ii) the day immediately preceding the day of the Issuer's next annual general meeting of shareholders. Read SEC document |
| June 28, 2022 Filed Jun 29, 2022 17:23 UTC |
AZAB MOHAMMADDirector
|
GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $30.11 | $0.00 |
DisclosureSEC source: 0001209191-22-039824 · doc4.xml · derivative · entry 1 AZAB MOHAMMAD · CIK 0001309653 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Shares · 18,000 shares Expires 2032-06-27 F1 · derivative.exercise_date: 100% of the common shares subject to the option will vest on the earlier of (i) the first anniversary of grant date and (ii) the day immediately preceding the day of the Issuer's next annual general meeting of shareholders. Read SEC document |
| June 28, 2022 Filed Jun 29, 2022 21:44 UTC |
Svoronos DawnDirector
|
GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $30.11 | $0.00 |
DisclosureSEC source: 0001209191-22-039836 · doc4.xml · derivative · entry 1 Svoronos Dawn · CIK 0001574579 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Shares · 18,000 shares Expires 2032-06-27 F1 · derivative.exercise_date: 100% of the common shares subject to the option will vest on the earlier of (i) the first anniversary of grant date and (ii) the day immediately preceding the day of the Issuer's next annual general meeting of shareholders. Read SEC document |
| June 28, 2022 Filed Jun 29, 2022 21:31 UTC |
GAROFALO ELIZABETH A.Director
|
GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $30.11 | $0.00 |
DisclosureSEC source: 0001209191-22-039829 · doc4.xml · derivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Shares · 18,000 shares Expires 2032-06-27 F1 · derivative.exercise_date: 100% of the common shares subject to the option will vest on the earlier of (i) the first anniversary of grant date and (ii) the day immediately preceding the day of the Issuer's next annual general meeting of shareholders. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 20:13 UTC |
KENNEY CHRISTOPHER JOHNChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $30.01 | $0.00 |
DisclosureSEC source: 0001209191-22-018449 · doc4.xml · derivative · entry 1 KENNEY CHRISTOPHER JOHN · CIK 0001880129 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2032-03-09 F1 · derivative.exercise_date: Vesting 25% on January 1, 2023 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 16:11 UTC |
AULIN SHERRYChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $30.01 | $0.00 |
DisclosureSEC source: 0001209191-22-018445 · doc4.xml · derivative · entry 1 AULIN SHERRY · CIK 0001862144 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2032-03-09 F1 · derivative.exercise_date: Vesting 25% on January 1, 2023 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 16:20 UTC |
PIMSTONE SIMON N.Director · Executive Chair
|
GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $30.01 | $0.00 |
DisclosureSEC source: 0001209191-22-018457 · doc4.xml · derivative · entry 1 PIMSTONE SIMON N. · CIK 0001620084 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires 2032-03-09 F1 · derivative.exercise_date: Vesting 25% on January 1, 2023 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 20:24 UTC |
Von Seggern ChristopherChief Commercial Officer
|
GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $30.01 | $0.00 |
DisclosureSEC source: 0001209191-22-018467 · doc4.xml · derivative · entry 1 Von Seggern Christopher · CIK 0001821192 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2032-03-09 F1 · derivative.exercise_date: Vesting 25% on January 1, 2023 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 20:21 UTC |
ROBIN SHERRINGTONEVP, Strategy & Innovation
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $30.01 | $0.00 |
DisclosureSEC source: 0001209191-22-018463 · doc4.xml · derivative · entry 1 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2032-03-09 F1 · derivative.exercise_date: Vesting 25% on January 1, 2023 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 20:15 UTC |
MORTIMER IANDirector · PRESIDENT & CEO
|
GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $30.01 | $0.00 |
DisclosureSEC source: 0001209191-22-018453 · doc4.xml · derivative · entry 1 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Shares · 400,000 shares Expires 2032-03-09 F1 · derivative.exercise_date: Vesting 25% on January 1, 2023 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 20:10 UTC |
EMPFIELD JAMES R.EVP, Drug Discovery
|
GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $30.01 | $0.00 |
DisclosureSEC source: 0001209191-22-018440 · doc4.xml · derivative · entry 1 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Shares · 65,000 shares Expires 2032-03-09 F1 · derivative.exercise_date: Vesting 25% on January 1, 2023 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 08, 2022 Filed Mar 8, 2022 19:58 UTC |
PIMSTONE SIMON N.Director
|
SaleCommon Shares | 2,500 | $30.50 | $76,250.00 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 19 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,135 Read SEC document |
| March 08, 2022 Filed Mar 8, 2022 19:58 UTC |
PIMSTONE SIMON N.Director
|
SaleCommon Shares | 2,500 | $30.55 | $76,375.00 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 18 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,635 F11 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.55 to $30.65, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein Read SEC document |
| March 08, 2022 Filed Mar 8, 2022 19:58 UTC |
PIMSTONE SIMON N.Director
|
SaleCommon Shares | 2,500 | $30.20 | $75,500.00 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 17 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,135 Read SEC document |
| March 08, 2022 Filed Mar 8, 2022 19:58 UTC |
PIMSTONE SIMON N.Director
|
SaleCommon Shares | 2,500 | $30.10 | $75,250.00 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 16 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,635 Read SEC document |
| March 08, 2022 Filed Mar 8, 2022 19:58 UTC |
PIMSTONE SIMON N.Director
|
SaleCommon Shares | 2,500 | $3.80 | $9,500.00 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 15 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,135 F10 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.800 to $30.880, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 08, 2022 Filed Mar 8, 2022 19:58 UTC |
PIMSTONE SIMON N.Director
|
SaleCommon Shares | 2,051 | $30.60 | $62,760.60 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 14 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,635 Read SEC document |
| March 08, 2022 Filed Mar 8, 2022 21:41 UTC Amendment |
PIMSTONE SIMON N.Director
|
SaleCommon Shares | 2,500 | $30.80 | $77,000.00 |
DisclosureSEC source: 0001209191-22-017418 · doc4a.xml · nonDerivative · entry 1 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,135 F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.800 to $30.880, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 19:58 UTC |
PIMSTONE SIMON N.Director
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 20,576 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · derivative · entry 21 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 20,576 shares Expires 2022-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. F12 · derivative.exercise_date: 25% of the shares subject to the Option vested on the one year anniversary of January 1, 2012 (the "2012 Vesting Commencement Date") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the 2012 Vesting Commencement Date. F13 · derivative.expiration_date: Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 19:58 UTC |
PIMSTONE SIMON N.Director
|
SaleCommon Shares | 2,500 | $30.55 | $76,375.00 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 13 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,686 Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 19:58 UTC |
PIMSTONE SIMON N.Director
|
SaleCommon Shares | 7,500 | $30.50 | $228,750.00 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 12 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,186 Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 19:58 UTC |
PIMSTONE SIMON N.Director
|
SaleCommon Shares | 2,500 | $30.52 | $76,300.00 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 11 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,686 Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 19:58 UTC |
PIMSTONE SIMON N.Director
|
SaleCommon Shares | 4,516 | $30.44 | $137,467.04 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 10 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,186 F9 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.40 to $30.50, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 19:58 UTC |
PIMSTONE SIMON N.Director
|
SaleCommon Shares | 4,516 | $30.45 | $137,512.20 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 9 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,702 F8 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.4100 to $30.4750, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 19:58 UTC |
PIMSTONE SIMON N.Director
|
SaleCommon Shares | 4,517 | $30.49 | $137,723.33 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 8 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,218 F7 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.480 to $30.645, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 19:58 UTC |
PIMSTONE SIMON N.Director
|
SaleCommon Shares | 5,037 | $30.60 | $154,132.20 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 7 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,735 F6 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.4865 to $30.67, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 19:58 UTC |
PIMSTONE SIMON N.Director
|
Tax withholdingCommon Shares | 1,990 | $30.23 | $60,157.70 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 6 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,772 F5 · price: Represents the closing price of the Company's common shares on March 4, 2022, which was converted to a Canadian dollar amount for purposes of net settlement calculations. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 19:58 UTC |
PIMSTONE SIMON N.Director
|
Exercise / conversionCommon Shares | 20,576 | $3.67 | $75,513.92 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 5 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 00:32 UTC |
EMPFIELD JAMES R.EVP, Drug Discovery
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $6.76 | $0.00 |
DisclosureSEC source: 0001209191-22-017316 · doc4.xml · derivative · entry 12 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 40,000 shares Expires 2026-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Vesting 25% on February 9, 2017 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 00:32 UTC |
EMPFIELD JAMES R.EVP, Drug Discovery
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $8.40 | $0.00 |
DisclosureSEC source: 0001209191-22-017316 · doc4.xml · derivative · entry 11 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,500 shares Expires 2027-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Vesting 25% on January 1, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 00:32 UTC |
EMPFIELD JAMES R.EVP, Drug Discovery
|
SaleCommon Shares | 31,048 | $30.54 | $948,205.92 |
DisclosureSEC source: 0001209191-22-017316 · doc4.xml · nonDerivative · entry 9 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.5161 to $30.6208, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 00:32 UTC |
EMPFIELD JAMES R.EVP, Drug Discovery
|
SaleCommon Shares | 1,805 | $30.62 | $55,269.10 |
DisclosureSEC source: 0001209191-22-017316 · doc4.xml · nonDerivative · entry 8 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,048 Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 00:32 UTC |
EMPFIELD JAMES R.EVP, Drug Discovery
|
Tax withholdingCommon Shares | 8,952 | $30.23 | $270,618.96 |
DisclosureSEC source: 0001209191-22-017316 · doc4.xml · nonDerivative · entry 7 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,853 F3 · price: Represents the closing price of the Company's common shares on March 4, 2022 which was converted to a Canadian dollar amount for purposes of net settlement calculations. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 00:32 UTC |
EMPFIELD JAMES R.EVP, Drug Discovery
|
Exercise / conversionCommon Shares | 40,000 | $6.76 | $270,400.00 |
DisclosureSEC source: 0001209191-22-017316 · doc4.xml · nonDerivative · entry 6 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 00:32 UTC |
EMPFIELD JAMES R.EVP, Drug Discovery
|
Tax withholdingCommon Shares | 695 | $30.23 | $21,009.85 |
DisclosureSEC source: 0001209191-22-017316 · doc4.xml · nonDerivative · entry 5 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,805 F3 · price: Represents the closing price of the Company's common shares on March 4, 2022 which was converted to a Canadian dollar amount for purposes of net settlement calculations. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 00:32 UTC |
EMPFIELD JAMES R.EVP, Drug Discovery
|
Exercise / conversionCommon Shares | 2,500 | $8.40 | $21,000.00 |
DisclosureSEC source: 0001209191-22-017316 · doc4.xml · nonDerivative · entry 4 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 19:58 UTC |
PIMSTONE SIMON N.Director
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,288 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · derivative · entry 20 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 10,288 shares Expires 2022-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. F12 · derivative.exercise_date: 25% of the shares subject to the Option vested on the one year anniversary of January 1, 2012 (the "2012 Vesting Commencement Date") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the 2012 Vesting Commencement Date. F13 · derivative.expiration_date: Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 19:58 UTC |
PIMSTONE SIMON N.Director
|
SaleCommon Shares | 4,793 | $30.56 | $146,474.08 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 4 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,186 F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.53 to $30.61, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 19:58 UTC |
PIMSTONE SIMON N.Director
|
SaleCommon Shares | 4,532 | $30.66 | $138,951.12 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 3 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,979 F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.49 to $30.97, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 19:58 UTC |
PIMSTONE SIMON N.Director
|
Tax withholdingCommon Shares | 963 | $31.42 | $30,257.46 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 2 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,511 F2 · price: Represents the closing price of the Company's common shares on March 3, 2022, which was converted to a Canadian dollar amount for purposes of net settlement calculations. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 19:58 UTC |
PIMSTONE SIMON N.Director
|
Exercise / conversionCommon Shares | 10,288 | $3.67 | $37,756.96 |
DisclosureSEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 1 PIMSTONE SIMON N. · CIK 0001620084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 00:32 UTC |
EMPFIELD JAMES R.EVP, Drug Discovery
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $8.40 | $0.00 |
DisclosureSEC source: 0001209191-22-017316 · doc4.xml · derivative · entry 10 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 25,000 shares Expires 2027-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Vesting 25% on January 1, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 00:32 UTC |
EMPFIELD JAMES R.EVP, Drug Discovery
|
SaleCommon Shares | 18,315 | $30.79 | $563,918.85 |
DisclosureSEC source: 0001209191-22-017316 · doc4.xml · nonDerivative · entry 3 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.21 to $31.0296, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 00:32 UTC |
EMPFIELD JAMES R.EVP, Drug Discovery
|
Tax withholdingCommon Shares | 6,685 | $31.42 | $210,042.70 |
DisclosureSEC source: 0001209191-22-017316 · doc4.xml · nonDerivative · entry 2 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,315 F1 · price: Represents the closing price of the Company's common shares on March 3, 2022 which was converted to a Canadian dollar amount for purposes of net settlement calculations. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 00:32 UTC |
EMPFIELD JAMES R.EVP, Drug Discovery
|
Exercise / conversionCommon Shares | 25,000 | $8.40 | $210,000.00 |
DisclosureSEC source: 0001209191-22-017316 · doc4.xml · nonDerivative · entry 1 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 00:35 UTC |
ROBIN SHERRINGTONEVP, Strategy & Innovation
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,172 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001209191-22-017318 · doc4.xml · derivative · entry 9 ROBIN SHERRINGTON · CIK 0001619962 · EVP, Strategy & Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 6,172 shares Expires 2022-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. F8 · derivative.exercise_date: 25% of the shares subject to the Option vested on the one year anniversary of January 1, 2012 (the "Second 2012 Vesting Commencement Date") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the Second 2012 Vesting Commencement Date F7 · derivative.expiration_date: Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.